The Medical Imaging & Technology Alliance (MITA)—the trade association representing manufacturers of medical imaging equipment, radiopharmaceuticals, contrast media, and focused ultrasound therapeutic devices—has submitted comments in response to the Centers for Medicare & Medicaid Services (CMS) Proposed Decision Memorandum for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease.
“MITA strongly believes the current proposal to limit coverage to randomized controlled trials in the hospital outpatient setting will significantly limit beneficiaries from accessing both current and potential innovations in Alzheimer’s treatment,” says Patrick Hope, executive director of MITA. “We encourage CMS to revisit this coverage determination with special consideration of its impact on innovation in the diagnosis, treatment and care for those Americans living with Alzheimer’s disease.”
In its comments, MITA also stressed its belief that Medicare’s final decision should allow both coverage of amyloid PET and also ensure that the right patients will have access to amyloid reduction therapies.
To read MITA’s full comments, click here.
